Medicaments comprising glicentin as active ingredient

Details Medicaments comprising glicentin as active ingredient Medicaments comprising glicentin as active ingredient

1993-06-30

1997-04-01

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530324, A61K 3800, A61K 3826, C07K 1400, C07K 14605

Patent

active

056165587

ABSTRACT:
Agents for stimulating insulin secretion and for treating diabetes which comprise glicentin as an active ingredient.

REFERENCES:
Thieden et al., Biochemica & Biophysica Aeta, 675, 163-70 (1981).
Holst, J., Gastro N erologer, 84, 1602-13, (1983).
Marco et al., J. Clin. Endocr. 33, 318 (1971).
Ahren, B. and I. Lundquist, Horm. Net. Res. 12, 582-586 (1986).
Ohneda et al, Chemical Abstracts, vol. 105, No. 17, 27 Oct. 1986, Columbus, Ohio, Abstract No. 146676, "Effect of Glicentin-Related Peptides on Glucagon Secretion in Anesthetized Dogs", p. 115.
Holst et al, Febs Letters, vol. 211, No. 2, Jan. 1987, Amsterdam NL, "Truncated Glucagon-Lik e Peptide I, an Insulin-Releasing Hormone from the Distal Gut", pp. 169-174.
Ahren et al, Chemical Abstracts, vol. 94, No. 7, 16 Feb. 1981, COlumbu, Ohio, Abstract No. 416 70c, "Effects of Glicentine on Insulin Secretion", p. 69.
A. Ohneda, et al., Tohoku Journal of Experimental Medicine, vol. 129, 1979, pp. 207-217.
A. Ohneda, et al., Diabetes, vol. 24, No. 9, 1975, pp. 811-819. "Glucagon Response to Arginine after Treatment of Diabetes Mellitus".
C. Morgan, et al., Diabetes, vol. 12, No. 2, 1963, pp. 115-126. "Immunoassay of Insulin: Two Antibody System".
A. Ohneda, et al., Horm. Metab. Res., vol. 9, 1977, pp. 447-452. "Effect of Intrapancreatic Administration of Vasocative Intestinal Peptide upon the release of Insulin and Glucagon in Dogs".
G. Bell, et al., Nature, vol. 304, Jul. 1983, pp. 368-371. "Exon duplication and divergence in the human preproglucagon gene".
A. Ohneda, et al., Horm. Metab. Res., vol. 8, 1976, pp. 170-174. "Purification of Canine Gut Glucagon-Like Immunoreactivity (GLI) and Its Insulin Releasing Activity".
D. D'Alessio, et al., Diabetes, vol. 38, Dec. 1989, pp. 1534-1538. "Effects of Glucagonlike Peptide I-(7-36) on Release of Insulin, Glucagon, and Somatostatin by Rat Pancreatic Islet Cell Monolayer Cultures".
T. Matsuyama, et al., Diabetes Research and Clinical Practice, vol. 5, 1988, pp. 281-284. "Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone".
R. Ebert, et al., Diabetes/Metabolism Reviews, vol. 3, No. 1, 1987, pp. 1-26. "Gastrointestinal Peptides and Insulin Secretion".
S. Seino, et al, FEBS, vol. 203, No. 1, Jul. 1986, pp. 25-30. "Mutations in the guinea pig preproglucagon gene are restricted to a specific portion of the prohormone sequence".
L. Thim, et al., Regulatory Peptides, 2 (1981), pp. 139-150. "The Primary Structure of Porcine Glicentin (Proglucagon)".
V. Mutt, et al, Advances in Metabolic Disorders, vol. 11, 1988, pp. 141-162. "Gastrointestinal Hormones".

Affiliated with

Also associated with

Rating

Medicaments comprising glicentin as active ingredient does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicaments comprising glicentin as active ingredient, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicaments comprising glicentin as active ingredient will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-538888